# Activity Screening of the HerbCaesalpinia sappan and an Analysis of Its Antitumor Effects

Authors: Yuan Li; Minghong Dong; Zijun Wu; Yongqi Huang; Haibing Qian; Cong Huang
Journal: Evidence-Based Complementary and Alternative Medicine
 (2021)

---

## Abstract

Aim. Traditionally, C. sappan medicine was the heartwood, which needs to be cut down as a whole. In this research, the antitumor activity and mechanisms of the leaves and stems were compared with the roots of Caesalpinia sappan; it was in order to investigate whether stems and leaves of C. sappan could be used to replace heartwood for antitumor treatment, thereby reducing resource destruction. Methods. MTT assays were used to identify the active sites of C. sappan based on the application of human liver cancer (HuH-7) cells. High-performance liquid chromatography (HPLC) was used to analyze polar extracts. We also established a H22 hepatoma-bearing mouse model by administering intraperitoneal injections of petroleum ether extracts from the leaves and stems (SY②) at doses of 20 and 65 mg/kg. Mice in the i.g. group were administered intragastrically with the same extracts (at doses of 100 and 325 mg/kg) at the same time (12 days). Results. The antitumor site of C. sappan was the petroleum ether extract. The IC50 for the petroleum ether extract of roots (SG②) was 56.10 μg/ml, while that for the leaves and stems (SY②) was 77.20 μg/ml. Grey relational analysis indicated 11 active fraction peaks that were closely related to antitumor activity. The size of tumors in H22 hepatoma-bearing mice was reduced significantly in mice administered with petroleum ether extracts from the leaves and stems (inhibition rates of high doses were 55.31% and 60.56%). Fibrous tissue proliferation, inflammatory cell infiltration, tumor cell necrosis, and the expression of proliferating cell nuclear antigen (PCNA) and vascular endothelial growth factor (VEGF) were all lower than in the control group (VEGF P < 0.001 and PCNA P < 0.05). Conclusion. Petroleum ether extracts of the roots, leaves, and stems of C. sappan exhibit certain antitumor effects. Our data indicate that the mechanisms underlying these effects may relate to a reduction in the expression of PCNA and VEGF and the inhibition of angiogenesis. Our findings indicate that we can expand the medicinal use of C. sappan to the leaves and stems, thus improving resource utilization and reducing resource damage.


---

## Body

## 1. Introduction

As a common Hmong medicine,Caesalpinia sappan is the dried heartwood of a legume used in Guizhou folk herbal medicine for the treatment of tumors. The roots and bark of C. sappan were listed as sources for a herbal drug in the 2019 edition of Quality Standards for Chinese Medicinal Materials and Ethnic Medicinal Materials in Guizhou Province. The main ingredients of C. sappan are flavonoids, diterpenes, lactones, coumarins, and amides. Recent research on C. sappan found that a crude water extract of C. sappan can inhibit a variety of cancer cells or induce their apoptosis [1–3], thus demonstrating the value of further development and utilization. Other research showed that an ethyl acetate extract of C. sappan had a significant inhibitory effect on the growth of HGC-27 cells [4]. Protosappanin B has been shown to exert an inhibitory effect on the proliferation of BTT, T24, HeLa, and SW480 tumor cells [5]. In addition, brazilin has been shown to significantly inhibit the growth and proliferation of human bladder T24 cancer cells; the mechanism involved may be related to the upregulation of C-Fos expression [6]. Brazilin not only inhibits the proliferation of skin cancer cells (A431, BCC, SCC25, and A375) but also can also promote apoptosis in skin cancer cells by activating the expression of caspase-3 [7]. A previous study of the effect of brazilin on the inhibition of growth and the induction of apoptosis in human glioblastoma U87 cells showed that brazilin promotes cell apoptosis by increasing the cleavage of PARA and by downregulating the expression levels of caspase-3 and caspase-7 [8]. In another study, investigating the invasion of mouse liver cancer H22 cells, both protosappanin B and mitomycin were found to increase the survival time of Kunming mice [9]. Brazilin was also shown to exhibit a potential inhibitory effect on the tumorigenicity of mouse lung cancer A549-FIG cells in BALB/c nude mice by inhibiting the phosphorylation of barrier-to-autointegration factor (BAF) [10].Traditionally, the roots and trunks ofC. sappan are used to make medicinal extracts. However, this practice causes irreversible damage to the trees and severe damage to the resource itself. There are no reports in the existing literature that compare extracts made from the roots of C. sappan with those made from the leaves and stems with regard to anticancer effects. In the present study, we compared the efficacy of petroleum ether extract prepared from the roots with leaves and stems of C. sappan to inhibit the growth of human liver cancer (HuH-7) cells and as an antitumor therapy for H22 tumor-bearing mice. In this paper, we provide experimental evidence that supports the preparation of medicinal extracts from the stems and leaves of C. sappan, thus expanding the way this resource is used and providing options to prevent damage from being incurred by these valuable trees.


## 2. Materials and Methods

### 2.1. Drugs and Reagents

Antibodies(PCNA (clone VG1) and VEGF (clone VG1)) were purchased from DAKO Company. Trypsin (batch no. SH30042.01), DMEM (batch no. NXKO731), and FBS (batch no. NXCO582) were purchased from HyClone. Fluorouracil was acquired from Tianjin Jinyao while acetonitrile (no. 20121018), methanol (batch no. 20120201), dimethyl sulfoxide (DMSO, batch no. 2012062), and phosphoric acid were purchased from Tianjin Kemiou Company. Epirubicin was provided by the Beijing Botai Company. Paraformaldehyde tissue fixation solution was provided by the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine.


### 2.2. Plant Material

Caesalpinia sappan (L.) Tod. plants were gathered from Ceheng County in Guizhou Province, China. The voucher specimen for C. sappan is GZTM 0018426 and is maintained in Guizhou University of Traditional Chinese Medicine, Guiyang.First, we ground 1.0 kg of dry leaves and stems fromC. sappan into a powder and then refluxed three times (75% ethanol, 5000 ml; 4 hours per reflux). The extracts were then mixed and concentrated; the ethanol extract yielded 143.0 g (SY①). The dregs were then dried and extracted with water three times. Next, we carried out six refluxes lasting 0.5 hours, 8 refluxes lasting 1 hour, and 12 refluxes lasting 2 hours. The solvent was then recovered so that we were left with the water extract; the yield of the water extract was 37.1 g (SY⑥). Different polar extracts were extracted from the ethanol extract, yielding 6.29 g of hydromethanolic extract (SY⑤), 3.15 g of n-butanol extract (SY④), 2.02 g of ethyl acetate extract (SY③), and 1.38 g of petroleum ether extract (SY②).This procedure was then repeated to prepare extracts from the roots ofC. sappan (1.0 kg). Using this strategy, we obtained 112.5 g of ethanol extract (SG①), 0.05 g of petroleum ether extract (SG②), 5.72 g of ethyl acetate extract (SG③), 1.12 g of n-butanol extract (SG④), 1.05 g of hydromethanolic extract (SG⑤), and 19.6 g of water extract (SG⑥).


### 2.3. Cell Lines

The H22 mouse liver cancer cell line and the human liver cancer HuH-7 cell line were purchased from the Shanghai Institute of Cell Research, Chinese Academy of Sciences. Dulbecco’s Modified Eagle Medium (DMEM) was used to preserve cells (the medium contained penicillin G (100 U/ml), FBS, streptomycin (100 U/ml), and L-glutamine (2 mM) mg/ml).


### 2.4. Animals

Our experiments involved male and female Kunming mice (certificate no. SCXU (Qian) 2015-0004, weighing 18–22 g). The Local Committee on Animal Care and Use approved the experimental procedures. All experimentation was conducted according to guidelines provided by the Committee for Ethics in Animal Research (CEPA). Mice were housed under standard conditions in a breeding room (12 h dark/light cycle; 20–25°C; 60–75% humidity) withad libitum access to food and water.


### 2.5. Determining the Effects ofC. sappan Extracts on the Inhibition of Human Liver Cancer HuH-7 Cell Proliferation

The effects ofC. sappan extracts were determined by MTT assays and by determining the IC50 of growth inhibition.


#### 2.5.1. MTT Assays

These assays were carried out as described previously [11, 12]. First, a cell suspension (1 × 105 cells/ml) was added to a 96-well plate. Then, 100 μl of each extract was placed in separate wells and placed in an incubator (5% CO2, 37°C) for 24 h. Water extracts and hydromethanolic extracts were dissolved with NS. DMSO (<0.1%) was used to aid the solubilization of n-butanol, ethyl acetate, and petroleum ether extracts. Administration groups were incubated with medicated serum (at doses of 100 μg/ml, 20 μg/ml, and 4 μg/ml); three replicates were set up for each group. After 48 h of incubation, 50 μl of MTT (5 mg/ml) was added to each well; this was followed by a 4 h incubation period. Next, the medium was removed and DMSO (150 μl) was added to each well. Absorbance was then tested by a Multiskan FC Microplate Reader (Thermo Fisher Scientific) at 570 nm. These experiments were repeated twice. Data were then used to calculate the cell proliferation inhibition rate (IR1), as shown in the following equation:(1)IR1=OD value of control group−OD value of experimental groupOD value of control group×100%.


#### 2.5.2. Determining the Antitumor Effects of Active Fractions

Based on preliminary experiments, the most effective active fractions were the petroleum ether extracts. Using equation (1), we determined the inhibition rate (IR1) of HuH-7 cells. Experimental groups featured a zero group (no cells), positive control groups (containing epirubicin at final concentrations of 20, 10, 5, 2.5, and 1.25 μg/ml), two fraction administration groups (at doses of 200, 100, 50, 25, and 12.5 μg/ml), and two control groups (PBS or DMSO).


### 2.6. High-Performance Liquid Chromatography (HPLC) Analysis

HPLC was used to investigate the stability, repeatability, and precision of all extracts. The RSD was less than 3.0%.


#### 2.6.1. Sample Solution Preparation

Samples of each polar extract (0.2 g) were weighed accurately and placed in different volumetric flasks (10 ml). A certain volume of methanol was then added into the volumetric flasks which were then shaken thoroughly. The samples were then sonicated for 30 mins and cooled at 20°C. The solutions were then filtered with a 0.45μm microporous membrane and used as test samples.


#### 2.6.2. Chromatographic Conditions

Extracts were analyzed by HPLC (Agilent 1100 with a quaternary pump and degasser, USA) in isocratic mode. All analyses were performed maintained at 25°C on an analytical Dima column (250 mm × 4.6 mm, 5 µm). The injection volume and flow rate were 10μl and 1.0 ml/min, respectively. Gradient elution was performed with mobile phases A (0.1% phosphoric acid), B (methanol), and C (acetonitrile) as follows: 0 min, 5% B and 5% C; 1 min, 15% B and 15% C; 60 min, 25% B and 25% C; 140 min, 33% B and 33% C; 270 min, 40% B and 40% C; 340 min, 45% B and 45% C; and 360 min, 50% B and 50% C. The detection wavelength was 240 nm.


### 2.7. The Mouse Tumor Model

H22 hepatoma-bearing mice were divided randomly into an intragastric (i.g.) low-dose group and high-dose group, a fluorouracil (FU) group, a control group, a low-dose group, and a high-dose group. On the basis of acute toxicity experiments, the SY② LD50 was 1961 mg/kg. The dose administered in the high-dose group (i.p.) was 1/30 of the LD50, the low-dose (i.p.) was 1/3 of the high dose. The dose administered to the high-dose group (i.g.) was 1/6 of the LD50 while the low-dose (i.g.) was 1/3 of the high-dose. At the end of the 12-day administration period, we measured pathological changes and measured the tumor weight. We also evaluated the expression of VEGF and PCNA in tumor tissues.


#### 2.7.1. Administration, Grouping, and Modeling

Ascites tumor-derived mice were produced by implanting H22 mouse hepatoma cells (0.2 ml/mouse) into the abdominal cavity. After 7 days, we used an injector to extract the nonbloody ascites which were then placed into an aseptic Petri dish [13]. Cells from the ascites were diluted to 1.0 × 107 cells/ml. Then, 0.2 ml of ascites was inoculated into the left anterior axillary of each mouse (2.0 × 106 tumor cells per mouse).In total, 60 mice were grouped as follows (n = 10 per group): i.g. low-dose group (100 mg/kg), i.g. high-dose group (325 mg/kg), FU group (83 mg/kg), control group, i.p. low-dose group (20 mg/kg), and i.p. high-dose group (65 mg/kg). SY② was administered to each mouse from the third day after vaccination (at a dose of 0.2 ml/10 g). All mice were euthanized on day 13. The tumor inhibition rate (IR2) was then determined by weighing the tumors and applying the following equation:(2)IR2=weight of tumorscontrol group−weight of tumorsdosing groupweight of tumorscontrol group×100%.


#### 2.7.2. Pathological Analysis of Tumor Tissue

Tumor tissue was fixed, dehydrated, embedded, sectioned, and then stained with hematoxylin-eosin (HE). A light microscope was then used to determine whether any pathological changes had occurred. Lesions were then assessed using a scoring system (3 points: lesions occupy > 50%; 2 points: lesions occupy 30–50%; 1 point: lesions occupy < 30%) used to assess pathological changes. We also evaluated a range of indicators, including fibrous tissue proliferation, inflammatory cell infiltration, and tumor cell necrosis.


#### 2.7.3. Assays to Determine the Expression of VEGF and PCNA

Immunohistochemistry was carried out in accordance with the manufacturer’s instructions using the following groupings: intragastric (i.g.), low-dose group, i.g. high-dose group, fluorouracil (FU) group, control group, intraperitoneal injection (i.p.) high-dose group, and i.p. low-dose group.Mice were sacrificed after 13 days of administration. The tumor tissues were then soaked, dehydrated, embedded, deparaffinized, and sectioned at 4μm. The sections were then incubated with VEGF, washed with PBS, soaked in 0.3% H2O2 buffer (30 min), washed, incubated in PBS (10 min), and then incubated with primary antibody for 20 min at 4°C. Sections were then washed with PBS (10 min), incubated with EnVision™ for 20 min, and then incubated with a color source substrate solution incubated for 20 min. Immunopositivity was indicated as brown/yellow particles located in the cytoplasm. Five dense areas of tissues (100 fields) of neovascularization were selected [14] and the number of microvessels in each view field-of-view (200 fields) were counted.Other portions of the tissue were immunohistochemically stained for PCNA. PCNA-positive protein (brown/yellow particles) were located in the nucleus. Five tissue areas were selected at random to count PCNA-positive tumor cells (400 fields).


### 2.8. Statistical Methods

Data were analyzed with SPSS version 23.0.P values of 0.05 or less were considered to be statistically significant. Data are presented as mean ± standard deviation (SD) for individual groups (n ≥ 3).


## 2.1. Drugs and Reagents

Antibodies(PCNA (clone VG1) and VEGF (clone VG1)) were purchased from DAKO Company. Trypsin (batch no. SH30042.01), DMEM (batch no. NXKO731), and FBS (batch no. NXCO582) were purchased from HyClone. Fluorouracil was acquired from Tianjin Jinyao while acetonitrile (no. 20121018), methanol (batch no. 20120201), dimethyl sulfoxide (DMSO, batch no. 2012062), and phosphoric acid were purchased from Tianjin Kemiou Company. Epirubicin was provided by the Beijing Botai Company. Paraformaldehyde tissue fixation solution was provided by the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine.


## 2.2. Plant Material

Caesalpinia sappan (L.) Tod. plants were gathered from Ceheng County in Guizhou Province, China. The voucher specimen for C. sappan is GZTM 0018426 and is maintained in Guizhou University of Traditional Chinese Medicine, Guiyang.First, we ground 1.0 kg of dry leaves and stems fromC. sappan into a powder and then refluxed three times (75% ethanol, 5000 ml; 4 hours per reflux). The extracts were then mixed and concentrated; the ethanol extract yielded 143.0 g (SY①). The dregs were then dried and extracted with water three times. Next, we carried out six refluxes lasting 0.5 hours, 8 refluxes lasting 1 hour, and 12 refluxes lasting 2 hours. The solvent was then recovered so that we were left with the water extract; the yield of the water extract was 37.1 g (SY⑥). Different polar extracts were extracted from the ethanol extract, yielding 6.29 g of hydromethanolic extract (SY⑤), 3.15 g of n-butanol extract (SY④), 2.02 g of ethyl acetate extract (SY③), and 1.38 g of petroleum ether extract (SY②).This procedure was then repeated to prepare extracts from the roots ofC. sappan (1.0 kg). Using this strategy, we obtained 112.5 g of ethanol extract (SG①), 0.05 g of petroleum ether extract (SG②), 5.72 g of ethyl acetate extract (SG③), 1.12 g of n-butanol extract (SG④), 1.05 g of hydromethanolic extract (SG⑤), and 19.6 g of water extract (SG⑥).


## 2.3. Cell Lines

The H22 mouse liver cancer cell line and the human liver cancer HuH-7 cell line were purchased from the Shanghai Institute of Cell Research, Chinese Academy of Sciences. Dulbecco’s Modified Eagle Medium (DMEM) was used to preserve cells (the medium contained penicillin G (100 U/ml), FBS, streptomycin (100 U/ml), and L-glutamine (2 mM) mg/ml).


## 2.4. Animals

Our experiments involved male and female Kunming mice (certificate no. SCXU (Qian) 2015-0004, weighing 18–22 g). The Local Committee on Animal Care and Use approved the experimental procedures. All experimentation was conducted according to guidelines provided by the Committee for Ethics in Animal Research (CEPA). Mice were housed under standard conditions in a breeding room (12 h dark/light cycle; 20–25°C; 60–75% humidity) withad libitum access to food and water.


## 2.5. Determining the Effects ofC. sappan Extracts on the Inhibition of Human Liver Cancer HuH-7 Cell Proliferation

The effects ofC. sappan extracts were determined by MTT assays and by determining the IC50 of growth inhibition.


### 2.5.1. MTT Assays

These assays were carried out as described previously [11, 12]. First, a cell suspension (1 × 105 cells/ml) was added to a 96-well plate. Then, 100 μl of each extract was placed in separate wells and placed in an incubator (5% CO2, 37°C) for 24 h. Water extracts and hydromethanolic extracts were dissolved with NS. DMSO (<0.1%) was used to aid the solubilization of n-butanol, ethyl acetate, and petroleum ether extracts. Administration groups were incubated with medicated serum (at doses of 100 μg/ml, 20 μg/ml, and 4 μg/ml); three replicates were set up for each group. After 48 h of incubation, 50 μl of MTT (5 mg/ml) was added to each well; this was followed by a 4 h incubation period. Next, the medium was removed and DMSO (150 μl) was added to each well. Absorbance was then tested by a Multiskan FC Microplate Reader (Thermo Fisher Scientific) at 570 nm. These experiments were repeated twice. Data were then used to calculate the cell proliferation inhibition rate (IR1), as shown in the following equation:(1)IR1=OD value of control group−OD value of experimental groupOD value of control group×100%.


### 2.5.2. Determining the Antitumor Effects of Active Fractions

Based on preliminary experiments, the most effective active fractions were the petroleum ether extracts. Using equation (1), we determined the inhibition rate (IR1) of HuH-7 cells. Experimental groups featured a zero group (no cells), positive control groups (containing epirubicin at final concentrations of 20, 10, 5, 2.5, and 1.25 μg/ml), two fraction administration groups (at doses of 200, 100, 50, 25, and 12.5 μg/ml), and two control groups (PBS or DMSO).


## 2.5.1. MTT Assays

These assays were carried out as described previously [11, 12]. First, a cell suspension (1 × 105 cells/ml) was added to a 96-well plate. Then, 100 μl of each extract was placed in separate wells and placed in an incubator (5% CO2, 37°C) for 24 h. Water extracts and hydromethanolic extracts were dissolved with NS. DMSO (<0.1%) was used to aid the solubilization of n-butanol, ethyl acetate, and petroleum ether extracts. Administration groups were incubated with medicated serum (at doses of 100 μg/ml, 20 μg/ml, and 4 μg/ml); three replicates were set up for each group. After 48 h of incubation, 50 μl of MTT (5 mg/ml) was added to each well; this was followed by a 4 h incubation period. Next, the medium was removed and DMSO (150 μl) was added to each well. Absorbance was then tested by a Multiskan FC Microplate Reader (Thermo Fisher Scientific) at 570 nm. These experiments were repeated twice. Data were then used to calculate the cell proliferation inhibition rate (IR1), as shown in the following equation:(1)IR1=OD value of control group−OD value of experimental groupOD value of control group×100%.


## 2.5.2. Determining the Antitumor Effects of Active Fractions

Based on preliminary experiments, the most effective active fractions were the petroleum ether extracts. Using equation (1), we determined the inhibition rate (IR1) of HuH-7 cells. Experimental groups featured a zero group (no cells), positive control groups (containing epirubicin at final concentrations of 20, 10, 5, 2.5, and 1.25 μg/ml), two fraction administration groups (at doses of 200, 100, 50, 25, and 12.5 μg/ml), and two control groups (PBS or DMSO).


## 2.6. High-Performance Liquid Chromatography (HPLC) Analysis

HPLC was used to investigate the stability, repeatability, and precision of all extracts. The RSD was less than 3.0%.


### 2.6.1. Sample Solution Preparation

Samples of each polar extract (0.2 g) were weighed accurately and placed in different volumetric flasks (10 ml). A certain volume of methanol was then added into the volumetric flasks which were then shaken thoroughly. The samples were then sonicated for 30 mins and cooled at 20°C. The solutions were then filtered with a 0.45μm microporous membrane and used as test samples.


### 2.6.2. Chromatographic Conditions

Extracts were analyzed by HPLC (Agilent 1100 with a quaternary pump and degasser, USA) in isocratic mode. All analyses were performed maintained at 25°C on an analytical Dima column (250 mm × 4.6 mm, 5 µm). The injection volume and flow rate were 10μl and 1.0 ml/min, respectively. Gradient elution was performed with mobile phases A (0.1% phosphoric acid), B (methanol), and C (acetonitrile) as follows: 0 min, 5% B and 5% C; 1 min, 15% B and 15% C; 60 min, 25% B and 25% C; 140 min, 33% B and 33% C; 270 min, 40% B and 40% C; 340 min, 45% B and 45% C; and 360 min, 50% B and 50% C. The detection wavelength was 240 nm.


## 2.6.1. Sample Solution Preparation

Samples of each polar extract (0.2 g) were weighed accurately and placed in different volumetric flasks (10 ml). A certain volume of methanol was then added into the volumetric flasks which were then shaken thoroughly. The samples were then sonicated for 30 mins and cooled at 20°C. The solutions were then filtered with a 0.45μm microporous membrane and used as test samples.


## 2.6.2. Chromatographic Conditions

Extracts were analyzed by HPLC (Agilent 1100 with a quaternary pump and degasser, USA) in isocratic mode. All analyses were performed maintained at 25°C on an analytical Dima column (250 mm × 4.6 mm, 5 µm). The injection volume and flow rate were 10μl and 1.0 ml/min, respectively. Gradient elution was performed with mobile phases A (0.1% phosphoric acid), B (methanol), and C (acetonitrile) as follows: 0 min, 5% B and 5% C; 1 min, 15% B and 15% C; 60 min, 25% B and 25% C; 140 min, 33% B and 33% C; 270 min, 40% B and 40% C; 340 min, 45% B and 45% C; and 360 min, 50% B and 50% C. The detection wavelength was 240 nm.


## 2.7. The Mouse Tumor Model

H22 hepatoma-bearing mice were divided randomly into an intragastric (i.g.) low-dose group and high-dose group, a fluorouracil (FU) group, a control group, a low-dose group, and a high-dose group. On the basis of acute toxicity experiments, the SY② LD50 was 1961 mg/kg. The dose administered in the high-dose group (i.p.) was 1/30 of the LD50, the low-dose (i.p.) was 1/3 of the high dose. The dose administered to the high-dose group (i.g.) was 1/6 of the LD50 while the low-dose (i.g.) was 1/3 of the high-dose. At the end of the 12-day administration period, we measured pathological changes and measured the tumor weight. We also evaluated the expression of VEGF and PCNA in tumor tissues.


### 2.7.1. Administration, Grouping, and Modeling

Ascites tumor-derived mice were produced by implanting H22 mouse hepatoma cells (0.2 ml/mouse) into the abdominal cavity. After 7 days, we used an injector to extract the nonbloody ascites which were then placed into an aseptic Petri dish [13]. Cells from the ascites were diluted to 1.0 × 107 cells/ml. Then, 0.2 ml of ascites was inoculated into the left anterior axillary of each mouse (2.0 × 106 tumor cells per mouse).In total, 60 mice were grouped as follows (n = 10 per group): i.g. low-dose group (100 mg/kg), i.g. high-dose group (325 mg/kg), FU group (83 mg/kg), control group, i.p. low-dose group (20 mg/kg), and i.p. high-dose group (65 mg/kg). SY② was administered to each mouse from the third day after vaccination (at a dose of 0.2 ml/10 g). All mice were euthanized on day 13. The tumor inhibition rate (IR2) was then determined by weighing the tumors and applying the following equation:(2)IR2=weight of tumorscontrol group−weight of tumorsdosing groupweight of tumorscontrol group×100%.


### 2.7.2. Pathological Analysis of Tumor Tissue

Tumor tissue was fixed, dehydrated, embedded, sectioned, and then stained with hematoxylin-eosin (HE). A light microscope was then used to determine whether any pathological changes had occurred. Lesions were then assessed using a scoring system (3 points: lesions occupy > 50%; 2 points: lesions occupy 30–50%; 1 point: lesions occupy < 30%) used to assess pathological changes. We also evaluated a range of indicators, including fibrous tissue proliferation, inflammatory cell infiltration, and tumor cell necrosis.


### 2.7.3. Assays to Determine the Expression of VEGF and PCNA

Immunohistochemistry was carried out in accordance with the manufacturer’s instructions using the following groupings: intragastric (i.g.), low-dose group, i.g. high-dose group, fluorouracil (FU) group, control group, intraperitoneal injection (i.p.) high-dose group, and i.p. low-dose group.Mice were sacrificed after 13 days of administration. The tumor tissues were then soaked, dehydrated, embedded, deparaffinized, and sectioned at 4μm. The sections were then incubated with VEGF, washed with PBS, soaked in 0.3% H2O2 buffer (30 min), washed, incubated in PBS (10 min), and then incubated with primary antibody for 20 min at 4°C. Sections were then washed with PBS (10 min), incubated with EnVision™ for 20 min, and then incubated with a color source substrate solution incubated for 20 min. Immunopositivity was indicated as brown/yellow particles located in the cytoplasm. Five dense areas of tissues (100 fields) of neovascularization were selected [14] and the number of microvessels in each view field-of-view (200 fields) were counted.Other portions of the tissue were immunohistochemically stained for PCNA. PCNA-positive protein (brown/yellow particles) were located in the nucleus. Five tissue areas were selected at random to count PCNA-positive tumor cells (400 fields).


## 2.7.1. Administration, Grouping, and Modeling

Ascites tumor-derived mice were produced by implanting H22 mouse hepatoma cells (0.2 ml/mouse) into the abdominal cavity. After 7 days, we used an injector to extract the nonbloody ascites which were then placed into an aseptic Petri dish [13]. Cells from the ascites were diluted to 1.0 × 107 cells/ml. Then, 0.2 ml of ascites was inoculated into the left anterior axillary of each mouse (2.0 × 106 tumor cells per mouse).In total, 60 mice were grouped as follows (n = 10 per group): i.g. low-dose group (100 mg/kg), i.g. high-dose group (325 mg/kg), FU group (83 mg/kg), control group, i.p. low-dose group (20 mg/kg), and i.p. high-dose group (65 mg/kg). SY② was administered to each mouse from the third day after vaccination (at a dose of 0.2 ml/10 g). All mice were euthanized on day 13. The tumor inhibition rate (IR2) was then determined by weighing the tumors and applying the following equation:(2)IR2=weight of tumorscontrol group−weight of tumorsdosing groupweight of tumorscontrol group×100%.


## 2.7.2. Pathological Analysis of Tumor Tissue

Tumor tissue was fixed, dehydrated, embedded, sectioned, and then stained with hematoxylin-eosin (HE). A light microscope was then used to determine whether any pathological changes had occurred. Lesions were then assessed using a scoring system (3 points: lesions occupy > 50%; 2 points: lesions occupy 30–50%; 1 point: lesions occupy < 30%) used to assess pathological changes. We also evaluated a range of indicators, including fibrous tissue proliferation, inflammatory cell infiltration, and tumor cell necrosis.


## 2.7.3. Assays to Determine the Expression of VEGF and PCNA

Immunohistochemistry was carried out in accordance with the manufacturer’s instructions using the following groupings: intragastric (i.g.), low-dose group, i.g. high-dose group, fluorouracil (FU) group, control group, intraperitoneal injection (i.p.) high-dose group, and i.p. low-dose group.Mice were sacrificed after 13 days of administration. The tumor tissues were then soaked, dehydrated, embedded, deparaffinized, and sectioned at 4μm. The sections were then incubated with VEGF, washed with PBS, soaked in 0.3% H2O2 buffer (30 min), washed, incubated in PBS (10 min), and then incubated with primary antibody for 20 min at 4°C. Sections were then washed with PBS (10 min), incubated with EnVision™ for 20 min, and then incubated with a color source substrate solution incubated for 20 min. Immunopositivity was indicated as brown/yellow particles located in the cytoplasm. Five dense areas of tissues (100 fields) of neovascularization were selected [14] and the number of microvessels in each view field-of-view (200 fields) were counted.Other portions of the tissue were immunohistochemically stained for PCNA. PCNA-positive protein (brown/yellow particles) were located in the nucleus. Five tissue areas were selected at random to count PCNA-positive tumor cells (400 fields).


## 2.8. Statistical Methods

Data were analyzed with SPSS version 23.0.P values of 0.05 or less were considered to be statistically significant. Data are presented as mean ± standard deviation (SD) for individual groups (n ≥ 3).


## 3. Results

### 3.1.C. sappan Extracts Inhibited the Proliferation of HuH-7 Cells

The antitumor results forC. sappan extracts are summarized in Table 1. Analysis showed that SY② and SG② significantly inhibited the proliferation of HuH-7 cells (Figures 1–3). These data indicated that C. sappan petroleum ether extracts (SY② and SG②) might be the most effective active fractions against tumors. The mean of the IC50 values for the duplicated experiments was taken as the final index for inhibition. The IC50 value of epirubicin, SY②, and SG②, were 5.11 μg/ml, 77.20 μg/ml, and 56.10 μg/ml (Table 2). The IC50 of SG② was smaller than that of SY②. Furthermore, the inhibitory effect of SY② was stronger than SG②.Table 1
The inhibitory effect ofC. sappan extracts (n = 6, mean ± SD).
GroupDose (μg/ml)OD valueIR1 (%)GroupDose (μg/ml)OD valueIR1 (%)NS—0.2353 ± 0.10870NS—0.2307 ± 0.10790DMSO—0.2018 ± 0.05720DMSO—0.1963 ± 0.05300SY②1000.0900 ± 0.0466∗55.4SG②1000.0830 ± 0.0656∗57.7200.1412 ± 0.046830.0200.1206 ± 0.0284∗38.640.1983 ± 0.06131.740.1880 ± 0.03664.2SY③1000.2028 ± 0.06100SG③1000.1912 ± 0.05482.6200.1938 ± 0.05364.0200.1918 ± 0.05792.340.2037 ± 0.0803040.2148 ± 0.05310SY④1000.2035 ± 0.06000SG④1000.1920 ± 0.05152.2200.2083 ± 0.06610200.2142 ± 0.0578040.2090 ± 0.0817040.1883 ± 0.05644.1SY⑤1000.2222 ± 0.09755.6SG⑤1000.2248 ± 0.09592.6200.2193 ± 0.08446.8200.2225 ± 0.08923.640.2253 ± 0.08354.240.2215 ± 0.08664.0SY⑥1000.2177 ± 0.09717.5SG⑥1000.2257 ± 0.09172.2200.2270 ± 0.09893.5200.2287 ± 0.09900.940.2387 ± 0.1039040.2210 ± 0.08254.2Note: compared with the DMSO control group,∗P<0.05.Figure 1
The inhibitory effect ofC. sappan extracts. (a) The roots of C. sappan. (b) The leaves and stems of C. sappan. Compared with the DMSO control group, ∗P<0.05.
(a)(b)Figure 2
Inhibition curves for SY② and SG②.Figure 3
HPLC chromatograms for water extract (SG⑥), hydromethanolic extract (SG⑤), n-butanol extract (SG④), ethyl acetate extract (SG③), and petroleum ether extract (SG②), prepared from the roots ofC. sappan.Table 2
The inhibitory effect of SY② and SG② (n = 3, mean ± SD).
GroupDose (μg/ml)First experimentSecond experimentOD valueIR1 (%)IC50 (μg/ml)OD valueIR1 (%)IC50 (μg/ml)PBS—0.1838 ± 0.00820—0.1860 ± 0.00680—DMSO—0.1752 ± 0.00280—0.1790 ± 0.01040—SY②2000.0500 ± 0.016471.576.60.0523 ± 0,016971.677.81000.0843 ± 0.046051.90.0912 ± 0.047050.5500.0990 ± 0.038043.50.1007 ± 0.043743.6250.1247 ± 0.019028.90.1300 ± 0.025129.512.50.1510 ± 0.031813.90.1607 ± 0.026712.8SG②2000.0390 ± 0.020477.756.050.0413 ± 0.021276.956.141000.0733 ± 0.045858.20.0700 ± 0.039660.9500.0841 ± 0.033852.00.0877 ± 0.036051.0250.1027 ± 0.031741.40.1053 ± 0.029141.212.50.1520 ± 0.021113.20.1560 ± 0.025012.8Epirubicin200.0289 ± 0.011283.55.420.0273 ± 0.010384.74.79100.0667 ± 0.010361.90.0657 ± 0.010463.350.0898 ± 0.018948.70.0839 ± 0.018353.12.50.1135 ± 0.012135.20.1102 ± 0.011838.51.250.1563 ± 0.013410.70.1545 ± 0.013313.6


### 3.2. HPLC Analysis

Figure3 shows an HPLC chromatogram of the polar extracts prepared from C. sappan roots. Compared with SG②, between 100 min and 410 min, SG④, SG⑤, and SG⑥ showed no chromatographic peaks. From 0 min to 130 min, SG③ had the most chromatographic peaks. This data implies that the roots had more components than the stems and leaves. The chromatogram of SY② was significantly different from the other four samples (Figure 4). When compared with SY③, SY④, SY⑤, and SY⑥, SY② showed no common peaks.Figure 4
HPLC chromatogram for water extract (SY⑥), hydromethanolic extract (SY⑤), n-butanol extract (SY④), ethyl acetate extract (SY③), and petroleum ether extract (SY②) prepared from the stems and leaves ofC. sappan.HPLC analysis found that 15906.1 and 13736.9 were the total peak areas for the active fractions (SG② and SY②). There were 26 common peaks (Figures5–9).Figure 5
A comparison of the petroleum ether extracts (SG② and SY②).Figure 6
Common peaks identified by HPLC for SG② and SY② (1–5).Figure 7
Common peaks identified by HPLC for SG② and SY② (6–13).Figure 8
Common peaks identified by HPLC for SG② and SY② (14–16).Figure 9
Common peaks identified by HPLC for SG② and SY② (17–35).


### 3.3. Grey Relational Analysis

Analysis showed that the most effective active fractions were the petroleum ether extracts ofC. sappan (SY② and SG②). The IC50 for HuH-7 cells was used as the pharmacodynamic index for active chemicals. We then used Grey correlation to analyze the association between antitumor activity and common peaks [15–17]. Analysis showed that the common peaks were correlated to antitumor activity (correlation coefficients > 0.6): 31 > 3 > 33 > 5 > 29 > 35 > 6 > 30 > 15 > 28 > 26 peaks (Table 3).Table 3
Correlation between common antitumor activity and peaks of activity.
PeakCorrelation10.35530.88950.73660.67080.40790.588100.354140.565150.629170.465190.499200.564220.484230.477240.441250.507260.622270.399280.626290.699300.667311.000320.593330.831340.489350.685


### 3.4. Analysis of Tumor Weight

Table4 and Figure 10(a) show that tumor weight in the FU group was significantly reduced compared with the control group (P<0.001); the high-dose i.p. group (P<0.001) and i.g. group (P<0.05) showed similar effects. This suggested that a high dose (i.g. and i.p.) could inhibit tumor growth. However, the weight of tumors in the low-dose groups (i.g. and i.p.) were not significantly different from the control group.Table 4
Tumor weight and IR2 (n = 10, mean ± SD).
GroupAdministration routesDose (mg/kg)Tumor weight (g)IR2 (%)Control groupi.p. + i.g.—1.607 ± 0.6241—FU groupi.p.830.352 ± 0.1862∗∗∗78.09i.p. groupi.p.650.624 ± 0.4143∗∗61.16201.000 ± 0.652837.77i.g. groupi.g.3250.707 ± 0.6373∗∗56.011000.995 ± 0.770938.08Note: compared with the control group,∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001.Figure 10
SY② antitumor effects in H22 hepatoma-bearing mice. All mice were administered for with SY② 12 days by the intragastric route (100 and 325 mg/kg), by intraperitoneal injection (20 and 65 mg/kg), and FU (83 mg/kg). (a) Tumor inhibition rate obtained by evaluating the weight of tumors,∗∗P<0.01 and ∗∗∗P<0.001 versus the control group. (b) Pathological scores for tumors (HE staining), ∗P<0.05 versus the control group. (c) VEGF expression, ∗∗∗P<0.001 versus the control group. (d) PCNA expression, ∗P<0.05 versus the control group.
(a)(b)(c)(d)


### 3.5. Pathological Scores of Tumors (HE Staining)

In the control group, tumor cells showed deep chromatin staining, irregular shapes, and polymorphism (Figures10(b) and 11). In the treatment groups, tumor cells showed differing extents of necrosis, fibrous tissue proliferation, and the infiltration of inflammatory cells. In the low-dose groups, there was no significant effect on pathological changes related to tumors. In the high-dose groups, there was a significant reduction in the lesion score (P<0.05) (Table 5 (a)).Figure 11
The antitumor effects of SY② in H22 hepatoma-bearing mice. All mice were administered with SY② for 12 days by the intragastric route (100 and 325 mg/kg), intraperitoneal injection (20 and 65 mg/kg), and by FU (83 mg/kg). Light microscopy 200x, bars = 100μm, for VEGF, PCNA, and HE staining.Table 5
Pathological changes in tumor tissue and the expression of VEGF and PCNA factors (n = 10, mean ± SD).
GroupDose (mg/kg)ScoresaVEGFbPCNAcControl group—4.31 ± 0.54174.915 ± 1.709163.13 ± 3.78FU group836.57 ± 0.43∗141.21 ± 0.9003∗∗∗46.12 ± 4.45∗i.p. group655.20 ± 0.46∗144.189 ± 1.0205∗∗∗52.80 ± 3.90∗204.30 ± 0.42131.066 ± 0.9191∗∗∗57.40 ± 2.82i.g. group3254.50 ± 0.17∗132.924 ± 1.7579∗∗∗48.70 ± 2.62∗1005.60 ± 0.43139.358 ± 1.3292∗∗∗41.10 ± 4.62aTumor cell lesion score (HE staining). bVEGF-positive tumor cells. cPCNA-positive tumor cells. Compared with the control group, ∗P<0.05 and ∗∗∗P<0.001.


### 3.6. VEGF Expression

Light microscopy showed that VEGF-positive products were localized in the cytoplasm and expressed in the cytoplasm of the arterial endothelial cells, small veins, and capillaries in tumors (Figures10(c) and 11). Angiogenesis in tumor tissue was significantly inhibited in the low-dose, high-doses, and FU injection groups (P<0.001) (Table 5 (b)).


### 3.7. PCNA Expression

Light microscopy detected PCNA-positive products in the nuclei (Figures10(d) and 11). The expression of PCNA in the high-dose groups was significantly lower (P<0.05) than in the control group (Table 5 (c)). Tumor cell proliferation was significantly inhibited in the i.p. and i.g. high-dose and FU injection groups.


## 3.1.C. sappan Extracts Inhibited the Proliferation of HuH-7 Cells

The antitumor results forC. sappan extracts are summarized in Table 1. Analysis showed that SY② and SG② significantly inhibited the proliferation of HuH-7 cells (Figures 1–3). These data indicated that C. sappan petroleum ether extracts (SY② and SG②) might be the most effective active fractions against tumors. The mean of the IC50 values for the duplicated experiments was taken as the final index for inhibition. The IC50 value of epirubicin, SY②, and SG②, were 5.11 μg/ml, 77.20 μg/ml, and 56.10 μg/ml (Table 2). The IC50 of SG② was smaller than that of SY②. Furthermore, the inhibitory effect of SY② was stronger than SG②.Table 1
The inhibitory effect ofC. sappan extracts (n = 6, mean ± SD).
GroupDose (μg/ml)OD valueIR1 (%)GroupDose (μg/ml)OD valueIR1 (%)NS—0.2353 ± 0.10870NS—0.2307 ± 0.10790DMSO—0.2018 ± 0.05720DMSO—0.1963 ± 0.05300SY②1000.0900 ± 0.0466∗55.4SG②1000.0830 ± 0.0656∗57.7200.1412 ± 0.046830.0200.1206 ± 0.0284∗38.640.1983 ± 0.06131.740.1880 ± 0.03664.2SY③1000.2028 ± 0.06100SG③1000.1912 ± 0.05482.6200.1938 ± 0.05364.0200.1918 ± 0.05792.340.2037 ± 0.0803040.2148 ± 0.05310SY④1000.2035 ± 0.06000SG④1000.1920 ± 0.05152.2200.2083 ± 0.06610200.2142 ± 0.0578040.2090 ± 0.0817040.1883 ± 0.05644.1SY⑤1000.2222 ± 0.09755.6SG⑤1000.2248 ± 0.09592.6200.2193 ± 0.08446.8200.2225 ± 0.08923.640.2253 ± 0.08354.240.2215 ± 0.08664.0SY⑥1000.2177 ± 0.09717.5SG⑥1000.2257 ± 0.09172.2200.2270 ± 0.09893.5200.2287 ± 0.09900.940.2387 ± 0.1039040.2210 ± 0.08254.2Note: compared with the DMSO control group,∗P<0.05.Figure 1
The inhibitory effect ofC. sappan extracts. (a) The roots of C. sappan. (b) The leaves and stems of C. sappan. Compared with the DMSO control group, ∗P<0.05.
(a)(b)Figure 2
Inhibition curves for SY② and SG②.Figure 3
HPLC chromatograms for water extract (SG⑥), hydromethanolic extract (SG⑤), n-butanol extract (SG④), ethyl acetate extract (SG③), and petroleum ether extract (SG②), prepared from the roots ofC. sappan.Table 2
The inhibitory effect of SY② and SG② (n = 3, mean ± SD).
GroupDose (μg/ml)First experimentSecond experimentOD valueIR1 (%)IC50 (μg/ml)OD valueIR1 (%)IC50 (μg/ml)PBS—0.1838 ± 0.00820—0.1860 ± 0.00680—DMSO—0.1752 ± 0.00280—0.1790 ± 0.01040—SY②2000.0500 ± 0.016471.576.60.0523 ± 0,016971.677.81000.0843 ± 0.046051.90.0912 ± 0.047050.5500.0990 ± 0.038043.50.1007 ± 0.043743.6250.1247 ± 0.019028.90.1300 ± 0.025129.512.50.1510 ± 0.031813.90.1607 ± 0.026712.8SG②2000.0390 ± 0.020477.756.050.0413 ± 0.021276.956.141000.0733 ± 0.045858.20.0700 ± 0.039660.9500.0841 ± 0.033852.00.0877 ± 0.036051.0250.1027 ± 0.031741.40.1053 ± 0.029141.212.50.1520 ± 0.021113.20.1560 ± 0.025012.8Epirubicin200.0289 ± 0.011283.55.420.0273 ± 0.010384.74.79100.0667 ± 0.010361.90.0657 ± 0.010463.350.0898 ± 0.018948.70.0839 ± 0.018353.12.50.1135 ± 0.012135.20.1102 ± 0.011838.51.250.1563 ± 0.013410.70.1545 ± 0.013313.6


## 3.2. HPLC Analysis

Figure3 shows an HPLC chromatogram of the polar extracts prepared from C. sappan roots. Compared with SG②, between 100 min and 410 min, SG④, SG⑤, and SG⑥ showed no chromatographic peaks. From 0 min to 130 min, SG③ had the most chromatographic peaks. This data implies that the roots had more components than the stems and leaves. The chromatogram of SY② was significantly different from the other four samples (Figure 4). When compared with SY③, SY④, SY⑤, and SY⑥, SY② showed no common peaks.Figure 4
HPLC chromatogram for water extract (SY⑥), hydromethanolic extract (SY⑤), n-butanol extract (SY④), ethyl acetate extract (SY③), and petroleum ether extract (SY②) prepared from the stems and leaves ofC. sappan.HPLC analysis found that 15906.1 and 13736.9 were the total peak areas for the active fractions (SG② and SY②). There were 26 common peaks (Figures5–9).Figure 5
A comparison of the petroleum ether extracts (SG② and SY②).Figure 6
Common peaks identified by HPLC for SG② and SY② (1–5).Figure 7
Common peaks identified by HPLC for SG② and SY② (6–13).Figure 8
Common peaks identified by HPLC for SG② and SY② (14–16).Figure 9
Common peaks identified by HPLC for SG② and SY② (17–35).


## 3.3. Grey Relational Analysis

Analysis showed that the most effective active fractions were the petroleum ether extracts ofC. sappan (SY② and SG②). The IC50 for HuH-7 cells was used as the pharmacodynamic index for active chemicals. We then used Grey correlation to analyze the association between antitumor activity and common peaks [15–17]. Analysis showed that the common peaks were correlated to antitumor activity (correlation coefficients > 0.6): 31 > 3 > 33 > 5 > 29 > 35 > 6 > 30 > 15 > 28 > 26 peaks (Table 3).Table 3
Correlation between common antitumor activity and peaks of activity.
PeakCorrelation10.35530.88950.73660.67080.40790.588100.354140.565150.629170.465190.499200.564220.484230.477240.441250.507260.622270.399280.626290.699300.667311.000320.593330.831340.489350.685


## 3.4. Analysis of Tumor Weight

Table4 and Figure 10(a) show that tumor weight in the FU group was significantly reduced compared with the control group (P<0.001); the high-dose i.p. group (P<0.001) and i.g. group (P<0.05) showed similar effects. This suggested that a high dose (i.g. and i.p.) could inhibit tumor growth. However, the weight of tumors in the low-dose groups (i.g. and i.p.) were not significantly different from the control group.Table 4
Tumor weight and IR2 (n = 10, mean ± SD).
GroupAdministration routesDose (mg/kg)Tumor weight (g)IR2 (%)Control groupi.p. + i.g.—1.607 ± 0.6241—FU groupi.p.830.352 ± 0.1862∗∗∗78.09i.p. groupi.p.650.624 ± 0.4143∗∗61.16201.000 ± 0.652837.77i.g. groupi.g.3250.707 ± 0.6373∗∗56.011000.995 ± 0.770938.08Note: compared with the control group,∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001.Figure 10
SY② antitumor effects in H22 hepatoma-bearing mice. All mice were administered for with SY② 12 days by the intragastric route (100 and 325 mg/kg), by intraperitoneal injection (20 and 65 mg/kg), and FU (83 mg/kg). (a) Tumor inhibition rate obtained by evaluating the weight of tumors,∗∗P<0.01 and ∗∗∗P<0.001 versus the control group. (b) Pathological scores for tumors (HE staining), ∗P<0.05 versus the control group. (c) VEGF expression, ∗∗∗P<0.001 versus the control group. (d) PCNA expression, ∗P<0.05 versus the control group.
(a)(b)(c)(d)


## 3.5. Pathological Scores of Tumors (HE Staining)

In the control group, tumor cells showed deep chromatin staining, irregular shapes, and polymorphism (Figures10(b) and 11). In the treatment groups, tumor cells showed differing extents of necrosis, fibrous tissue proliferation, and the infiltration of inflammatory cells. In the low-dose groups, there was no significant effect on pathological changes related to tumors. In the high-dose groups, there was a significant reduction in the lesion score (P<0.05) (Table 5 (a)).Figure 11
The antitumor effects of SY② in H22 hepatoma-bearing mice. All mice were administered with SY② for 12 days by the intragastric route (100 and 325 mg/kg), intraperitoneal injection (20 and 65 mg/kg), and by FU (83 mg/kg). Light microscopy 200x, bars = 100μm, for VEGF, PCNA, and HE staining.Table 5
Pathological changes in tumor tissue and the expression of VEGF and PCNA factors (n = 10, mean ± SD).
GroupDose (mg/kg)ScoresaVEGFbPCNAcControl group—4.31 ± 0.54174.915 ± 1.709163.13 ± 3.78FU group836.57 ± 0.43∗141.21 ± 0.9003∗∗∗46.12 ± 4.45∗i.p. group655.20 ± 0.46∗144.189 ± 1.0205∗∗∗52.80 ± 3.90∗204.30 ± 0.42131.066 ± 0.9191∗∗∗57.40 ± 2.82i.g. group3254.50 ± 0.17∗132.924 ± 1.7579∗∗∗48.70 ± 2.62∗1005.60 ± 0.43139.358 ± 1.3292∗∗∗41.10 ± 4.62aTumor cell lesion score (HE staining). bVEGF-positive tumor cells. cPCNA-positive tumor cells. Compared with the control group, ∗P<0.05 and ∗∗∗P<0.001.


## 3.6. VEGF Expression

Light microscopy showed that VEGF-positive products were localized in the cytoplasm and expressed in the cytoplasm of the arterial endothelial cells, small veins, and capillaries in tumors (Figures10(c) and 11). Angiogenesis in tumor tissue was significantly inhibited in the low-dose, high-doses, and FU injection groups (P<0.001) (Table 5 (b)).


## 3.7. PCNA Expression

Light microscopy detected PCNA-positive products in the nuclei (Figures10(d) and 11). The expression of PCNA in the high-dose groups was significantly lower (P<0.05) than in the control group (Table 5 (c)). Tumor cell proliferation was significantly inhibited in the i.p. and i.g. high-dose and FU injection groups.


## 4. Discussion

In this study, HPLC chromatograms demonstrated that there were similar chemical components in the roots, stems, and leaves. We also used the Grey relational analysis to evaluate the relative contribution of each component to tumor suppression; 11 common peaks were shown to be correlated with tumor inhibition activity. These components exhibited a congenerous antitumor effect that was consistent with the advantages of traditional Chinese medicine (multicomponents and multitargets) [18]. Analysis showed that a C. sappan represented a key resource for a large number of antitumor compounds, thus providing a useful foundation for future research focusing on identifying compounds with antitumor activity.Tables1 and 2 show that the petroleum ether extract of C. sappan exhibited the best antitumor activity. The petroleum ether extract of leaves and stems (SY②) significantly inhibited the proliferation of tumor cells with an IC50 of 77.20 μg/ml; this was even better than the roots, the resource that is traditionally used to prepare extracts (roots: SG②; IC50 = 56.10 μg/ml). Therefore, it follows that leaves and stems could also be used as a medicine for antitumor therapy. The Grey relational analysis indicated that 11 active fractions exhibited common peaks (31#, 3#, 33#, 5#, 29#, 35#, 6#, 30#, 15#,28#, and 26#) that were closely related to antitumor activity. This foundation was used in the next step of our research which focused on extracting, isolating, and identifying compounds with antitumor activity.There was a significant reduction in the tumor tissue of H22 hepatoma-bearing mice in response to high-dose administration (Table4). Tumor cells in the control group showed deep chromatin staining, irregular shapes, and polymorphism (Figures 10(b) and 11). In the treatment groups, the tumor cells exhibited differing degrees of necrosis, fibrous tissue proliferation, and the infiltration of inflammatory cells. The lesion score for tumor cells in the high-dose groups was significantly lower than in the other groups, thus showing that the petroleum ether extract of leaves and stems had a reliable and precise antitumor effect in vivo. Compared to other groups, the high-dose treatment groups showed reduced fibrous tissue proliferation, inflammatory cell infiltration, and necrosis in tumor cells; these groups also showed reduced expression of PCNA and VEGF.Excessive proliferation and distant metastasis are important biological characteristics of malignant tumors. Therefore, developing methods to inhibit the proliferation of tumor cells and prevent their distant metastasis has become the main focus of clinical treatment. PCNA, VEGF, and other factors play important roles in promoting tumor proliferation and metastasis, PCNA is a cyclin, an accessory protein for cell DNA polymerase that exists in each developmental stage of tumor cells and the normal proliferation cycle of cells. However, PCNA is expressed at low levels in the G0 and G1 phases. The expression of PCNA begins in the G1 phase and reaches a peak in the S phase but decreases significantly in the M and G2 phases. This means that the changes in PCNA expression are consistent with DNA synthesis and are one of the most effective markers for detecting cell proliferation. PCNA expression can directly reflect the proliferation of tumor cells. The higher the expression of PCNA, the more active the state of cell proliferation; therefore, PCNA is regarded as being a useful indicator of the proliferation status of a cell [19–21]. Many studies have shown that the metastasis and growth of tumor tissue are dependent on a sufficient nutrient supply, new blood vessels, and oxygen. On the other hand, due to the high permeability of new blood vessels, tumor cells can readily pass through and spread. Revascularization provides conditions for infiltration and metastasis [22]. The VEGF family are members of the receptor tyrosine kinase (RTK) family and play a key role in tumor angiogenesis. Consequently, VEGF is one of the most important inducers of angiogenesis and increases vascular permeability. Once VEGF binds to its corresponding receptor, it stimulates the proliferation of vascular endothelial cells in the tumor and increases vascular permeability to provide a suitable basis for tumor infiltration and metastasis; consequently, VEGF is one of the main targets for tumor therapy [23].We showed that the petroleum ether extract of leaves and stems could significantly inhibit the proliferation of tumor cellsin vivo. Our data also demonstrated that, within the treatment groups, each dose inhibited the proliferation of tumors and that there was a significant reduction of tumor size compared to the model group; there was also a reduction in the extent of pathological changes. Immunohistochemical staining showed that the number of PCNA-positive cells within the tumor tissue was lower than in the model group, thus indicating that the mechanism underlying the inhibitory effect of SBLPE on tumor proliferation may be related to the inhibition of high PCNA expression. SBLPE was shown to inhibit the expression of VEGF in tumor tissues in an effective manner and that VEGF was the strongest angiogenesis-promoting factor and played a significant role in promoting the proliferation and metastasis of tumor tissues. Our data showed that SBLPE inhibited the expression of VEGF in vascular endothelial cells. Furthermore, our data indicated that SBLPE inhibited the growth and angiogenesis of H22 tumors in mice and helped to inhibit the distant metastasis of tumor cells through immature blood vessels. Combined with the expression of VEGF in SBLPE-treated tumor tissues, our data indicated that SBLPE may inhibit the growth and angiogenesis of H22 tumors by inhibiting the secretion of VEGF by tumor cells, therefore inhibiting the metastasis and proliferation of tumor cells.The mechanisms underlying tumor cell proliferation and metastasis are complicated. Our research only investigated the mechanisms underlying anti-H22 tumor effects by evaluating antitumor growth and the growth of microvessels. Further studies are now needed to confirm these mechanisms and identify associated pathways. However, it is important to note that SBLPE is still a mixture. Further studies are now needed to identify the effective ingredients in SBLPE. However, our results provide a meaningful basis for the further identification of effective substances with antitumor effects.


## 5. Conclusions

In this paper, we demonstrated, for the first time, that petroleum ether extracts prepared from the leaves and stems ofC. sappan can inhibit the proliferation of tumor cells. Compared with the resources that are traditionally used to prepare medical extracts (the roots and the trunk), the use of the stems and leaves would cause less damage to valuable resources. Therefore, our data indicates that the range of resources used to prepare extracts could be expanded to the leaves and stems, thus protecting valuable C. sappan resources.Petroleum ether extracts prepared from the leaves and stems ofC. sappan reduced the expression of PCNA and VEGF in the tumors of H22 hepatoma-bearing mice. Grey relational analysis indicated that the 11 common peaks of active fractions were closely related to antitumor activity. Our data provide a useful foundation for the extraction, isolation, and identification of compounds with antitumor activity.



---

*Source: 9939345-2021-06-28.xml*